CClinicalTrials.gg
Sign In
CompletedNCT05041465Updated Sep 13, 2021

The Cosmetic Effect of Mineral Clay Masks

An interventional study of Clay mask in Rhytides, sponsored by University of California, Davis. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-13.

Sponsored by University of California, Davis · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Jan 2019, registered Mar 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the cosmetic effects of commercially available mineral clay masks over a 4-week period. Changes in skin pigmentation, shine, wrinkles, and texture will be assessed.

A second aim of the study is to assess the safety and tolerability of mineral clay masks by assessing redness and participant feedback.

02

Conditions studied

  • Rhytides
03

In context

Lead sponsor

University of California, Davis is the lead sponsor of 798 studies on the registry; 146 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 43 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Individuals aged 18-50
  • Individuals in good general health
  • Individuals free of any autoimmune or systemic disorder, which would interfere with the analysis.

Exclusion criteria

Exclusion Criteria:

  • Individuals who have been on any topical prescribed medications for the past 2 weeks
  • Individuals who have history of acute or chronic disease that would likely interfere with or increase the risk on study participation at the discretion of the investigator
  • Individuals with active (flaring) disease or chronic skin allergies (atopic dermatitis/eczema) or those who have recently undergone treatment for skin cancer (within the last 12 months) in the area of testing on the forehead, nose and the cheeks
  • Female volunteers who are pregnant or planning to become pregnant over the course of the study. The risk to pregnant women is minimal but the facial appearance can be confounded by the altered hormones associated with pregnancy, as is well documented in chloasma which is dyspigmentation that arises in pregnancy. Women who become pregnant during the duration of the study will become ineligible but there are no birth control requirements.
  • Female volunteers who have started a new hormonal birth control agent or switched to a hormonal birth control agent within the past 60 days
  • Individuals who have had any medical or cosmetic procedure, such as laser resurfacing, or plastic surgery to the test site (face) within the last 6 months. This includes botulinum toxin, dermal fillers, collagen or other similar cosmetic procedure
  • Individuals who are currently using or during the past 14 days have used a retinoid such as tretinoin, adapalene, or retinol containing agents or a hydroquinone containing agent
  • Individuals who have used mineral clay masks on their face within the last 14 days
  • Individuals with a known history of hypersensitivity to any ingredients to the agent that is being assessed
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    French Green Clay Mask

    Other: Clay mask

  • Experimental
    Rhassoul Clay Mask

    Other: Clay mask

  • Experimental
    Bentonite Clay Mask

    Other: Clay mask

Interventions

  • OtherClay mask

    Clay mask powders- French green, Rhassul and bentonite

06

What researchers measure

Primary outcomes

  1. Count of Participants with Decrease in Skin pigmentation intensity at 4 Weeks

    Computer and photography based facial image analysis

    Time frame: 4 weeks

Secondary outcomes

  1. % of Participants with Skin redness intensity improvement at 4 weeks

    Computer and photography based facial image analysis

    Time frame: 4 weeks

Other outcomes

  1. Patient tolerability survey

    Survey to grade for side effects

    Time frame: 4 weeks

07

Study locations

1 site
  • University of California Davis
    Sacramento, California 95816, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05041465
Lead sponsor
University of California, Davis
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Jan 1, 2019
Primary completion
Dec 1, 2019
Completion
Mar 1, 2020
Last update
Sep 13, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University of California, Davis

Start the discussion